PerkinElmer Life Sciences Discloses Details of New ProteinArray Workstation

The First of its Kind Workstation that Fully Automates the Processing of Protein Microarrays

29-May-2002 - BOSTON, May 28, 2002 - PerkinElmer Life Sciences, a leading provider of drug discovery, life science research and clinical screening technologies and services, today disclosed details of the new ProteinArray Workstation(TM), the first workstation to completely automate the processing of ...

Amersham Biosciences Introduces Ettan DIGE Platform for 2-D Fluorescence Difference Gel Electrophoresis

A novel method for differential protein expression analysis

24-Apr-2002 - PISCATAWAY, NJ – April 23, 2002 - Amersham Biosciences, the life sciences business of Amersham plc has introduced Ettan TM DIGE, a new platform for its unique, patented technology for 2-Dimensional Fluorescence Difference Gel Electrophoresis (2-D DIGE). 2-D DIGE technology is already used by some ...

Caliper and Agilent Introduce Cell Assays for 2100 Bioanalyzer

09-Oct-2001 - Caliper Technologies Corp. and Agilent Technologies Inc. announce the introduction of a kit to perform cell analysis assays on the Agilent 2100 Bioanalyzer. Jointly developed by Caliper and Agilent, the new Cell Fluorescence LabChip® kit is intended for use by biochemists, molecular ...

MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration

Preferred Access to one of World´s Largest Human tissue banks

27-Sep-2001 - MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today an Agreement with Oridis Biomed Forschungs- und Entwicklungs GmbH, Graz, Austria, that will provide MorphoSys with preferred access to one of the world’s largest human tissue banks. The goal of the collaboration is ...

MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration

18-Sep-2001 - MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratagene to ...

Genmab, Medarex And Glaucus Announce Collaboration To Develop Human Antibody Therapeutics And Proteomics Technology

06-Apr-2001 - Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Medarex (Nasdaq:MEDX), and Glaucus Proteomics B.V., a privately-held company incorporated in The Netherlands, announced today that they have entered into a collaboration to develop new antibody therapeutic products to novel disease targets discovered ...